
News|Videos|December 18, 2024
Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL): DESTINY-Breast12 (DB-12) results
Author(s)Laura Huppert, MD
Dr. Laura Huppert presents key data from the DESTINY-Breast12 study, showcasing the effects of trastuzumab deruxtecan on health-related quality of life and neurological function in HER2+ metastatic breast cancer patients, with findings demonstrating preserved quality of life and neurological stability, regardless of brain metastasis status.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5


































